Research programme: synthetic biology therapeutics - Synlogic

Drug Profile

Research programme: synthetic biology therapeutics - Synlogic

Alternative Names: ci-di-AMP; SYN STING; SYN-MSUD; SYN-PKU; SYNB 1618; SYNB1010; Synthetic Biotic™ - Synlogic

Latest Information Update: 16 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Synlogic
  • Developer AbbVie; Synlogic
  • Class Probiotics
  • Mechanism of Action Ammonia scavengers; Metagenome modulators; MPYS-protein-stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Phenylketonuria
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Cancer; Hepatic encephalopathy; Inborn error metabolic disorders; Phenylketonuria
  • Research Acidaemia; Inflammatory bowel diseases; Maple syrup urine disease; Non-alcoholic steatohepatitis

Most Recent Events

  • 20 Mar 2018 Synlogic plans the phase I/IIa SAD/MAD trial for SYNB 1618 in Phenylketonuria (In volunteers) in 1H 2018
  • 12 Mar 2018 Pharmacodynamics data from a preclinical trial in Phenylketonuria released by Synlogic
  • 13 Feb 2018 Preclinical trials in Cancer in USA (Intratumoural)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top